Biotech Startups

Obulytix develops Precision Lysin Therapeutics, a novel class of engineered biologics designed to target multidrug-resistant Gram-negative bacteria for severe bloodstream and lung infections. The company was founded as a spin-off from Ghent University and KU Leuven to address antimicrobial resistance in healthcare.

1 investor

Oceanium develops proprietary seaweed-based ingredients for food, health, and materials using innovative biorefinery and green chemistry processes. The company serves the food, health, and materials industries while advancing ocean health and coastal sustainability across the Western Hemisphere.

1 investor

Octarine Bio is a synthetic biology platform company that engineers microorganisms to produce bio-based, low-impact ingredients and materials to replace unsustainable synthetic chemical processes across industries including pharmaceuticals, chemicals, food, and energy. Founded in 2018 based on research from Danish universities, the company applies precision fermentation and enzymatic enhancement to develop commercial-scale bio-manufacturing solutions.

1 investor

Ocugenix is a biotechnology company developing ophthalmology therapeutics based on NIH-funded research into the molecular mechanisms of wound healing and cellular response, originating from a research team at the University of Pittsburgh Medical Center. Its focus areas include eye diseases such as glaucoma and retinal conditions.

1 investor

Ocutec is a life sciences company developing advanced materials and technologies for contact lenses and ophthalmic applications. It works in the medical device and biomaterials space.

1 investor

Ocutheia offers biotechnology consulting services with expert biotechnologists providing tailored solutions to clients.

1 investor

OIS is a conference and community, active since 2009, focused on eye care and ophthalmology innovation, connecting startups, strategics, investors, and clinicians. It provides curated programming, networking, and access to new technologies in the ophthalmology industry.

1 investor

Okami Medical develops the LOBO vascular occlusion system, an occluder built on high-density, small-pore HDBRAID technology for fast arterial occlusion in the peripheral vasculature, along with SENDERO microcatheters and delivery catheters. Its products are intended for physicians treating peripheral vascular conditions.

1 investor

Okanagan Specialty Fruits uses biotechnology to develop fruit varieties aimed at more efficient and sustainable food production. The company operates in the agricultural biotechnology space.

1 investor

Okava develops medicines for dogs and cats by adapting established human pharmaceuticals for veterinary use, targeting conditions such as obesity, diabetes, arthritis, and chronic inflammation. The company operates in the animal health and pet pharmaceutical sector.

1 investor

okom wrks labs develops regenerative building materials, focusing on load-bearing structural components made from mycelium, hemp hurd, and organic cotton as sustainable substitutes for materials tied to deforestation. The company applies regenerative design principles to construction and material science challenges.

1 investor

Olaris develops diagnostics that analyze metabolite signatures by combining metabolomics, machine learning, and biology to understand disease processes. The company works to identify clinically useful metabolite signatures.

1 investor

Olatec develops a pharmaceutical platform targeting acute and chronic inflammatory diseases, with its lead compound dapansutrile (OLT1177), a NLRP3 inhibitor currently in Phase 2 clinical trials in the US and Europe.

1 investor

Oleos operates a biomanufacturing platform that converts non-edible biomass waste into low-carbon fuel feedstocks, including cellulosic sugars and renewable oils (triacylglycerols). These feedstocks are used to produce advanced fuels such as ethanol, renewable diesel, and sustainable aviation fuel via HEFA and alcohol-to-jet pathways.

1 investor

Oleo operates a biomanufacturing platform that converts non-edible biomass waste into low-carbon feedstocks—cellulosic sugars and renewable oils—for producing ethanol, renewable diesel, and sustainable aviation fuel. Its products target advanced fuel producers across aviation and marine shipping, supporting both HEFA and alcohol-to-jet SAF pathways.

1 investor

Olfactive Biosolutions develops Pivit, a product platform that applies receptor science to consumer food and beverage products by translating natural food molecules into targeted physiological outcomes.

1 investor

Oligofeed is a science-based company that applies over a decade of academic research to animal health, developing products for real-world livestock and animal health challenges.

1 investor

Oligomerix is a biopharmaceutical company developing therapeutic compounds, with leadership focused on advancing drug candidates through clinical development stages.

1 investor

Oligon Therapeutics develops RNA-based multi-targeting drugs using its SeekR platform, which combines RNA aptamer oligo-binders with siRNA silencers into a single self-delivering molecule for precise targeting of specific cell types, including T-cells and cancer cells. The biotechnology company applies AI-based molecular modeling to discover and optimize these RNA drug candidates.

1 investor

Oligotune is developing RNA-based cancer immunotherapy treatments that target solid tumours with enhanced precision. The company uses a data-driven pre-clinical R&D pipeline to address mechanisms in cancer immunotherapy that existing treatments do not adequately target.

1 investor

Olive Capital is a seed-stage venture capital firm that invests in founders building in synthetic biology, software, and emerging platforms.

1 investor

Olivo Sciences licenses de-identified multimodal patient data (multi-omics, imaging, clinical, and wearable) and provides domain-trained AI models for biopharma companies across the drug development cycle, with a focus on brain and neurological disorders. It supports target discovery, clinical trial design and enrollment, and post-marketing real-world evidence generation.

1 investor

A clinical-stage biotechnology company focused on therapies for vision-threatening conditions including wet AMD and diabetic macular edema.

1 investor

Omerna Biosolutions develops a dsRNA-based anti-fungal crop protection product that is targeted, non-GMO, and non-toxic, and can be combined with traditional fungicides to control fungal pathogens and extend shelf life. The company serves agriculture, targeting crop loss from fungal pathogens, and is based on technology from the Volcani and Weizmann Institutes in Israel.

1 investor